Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 17/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14585687 | 1.00 | S1PR3 (0.42) | S1PR3S1PR4BRD4S1PR2S1PR1 | |
| SCHEMBL14033601 | 0.85 | S1PR3 (0.45) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL4602819 | 0.81 | S1PR3 (0.43) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL14625821 | 0.80 | S1PR3 (0.42) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL19138122 | 0.78 | S1PR3 (0.37) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL5514077 | 0.77 | S1PR3 (0.48) | S1PR3S1PR4S1PR2 | |
| SCHEMBL4602097 | 0.76 | MEN1 (0.42) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL14585679 | 0.76 | MEN1 (0.42) | S1PR3S1PR4S1PR2S1PR1MEN1 | |
| SCHEMBL14623454 | 0.75 | S1PR3 (0.49) | S1PR3S1PR4BRD4S1PR2S1PR1 | |
| SCHEMBL27296578 | 0.75 | NR3C1 (0.36) | S1PR3S1PR4S1PR2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924568-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1915351-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2007011623-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007011618-A1 | QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT | SCHERING CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | SCHERING CORPORATION | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015774-A1 | Quinazoline derivatives useful in cancer treatment | TP53, TP53BP1, ACIN1 | S1PR3 1297/4885S1PR4 3232/4885BRD4 245/4885 |
| US-20070032502-A1 | Quinazoline derivatives useful in cancer treatment | TP53, ACIN1, TP53BP1 | S1PR3 1396/4885S1PR4 3216/4885BRD4 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.